Cargando…

Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment

SIMPLE SUMMARY: Indeterminate pulmonary nodules detected by computer tomography are a common clinical finding, but the path to determine malignancy can cause harm to patients. We aimed to comprehensively assess other types of noninvasive information that could help clinicians diagnose lung cancer, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lastwika, Kristin J., Wu, Wei, Zhang, Yuzheng, Ma, Ningxin, Zečević, Mladen, Pipavath, Sudhakar N. J., Randolph, Timothy W., Houghton, A. McGarry, Nair, Viswam S., Lampe, Paul D., Kinahan, Paul E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341085/
https://www.ncbi.nlm.nih.gov/pubmed/37444527
http://dx.doi.org/10.3390/cancers15133418
_version_ 1785072178257985536
author Lastwika, Kristin J.
Wu, Wei
Zhang, Yuzheng
Ma, Ningxin
Zečević, Mladen
Pipavath, Sudhakar N. J.
Randolph, Timothy W.
Houghton, A. McGarry
Nair, Viswam S.
Lampe, Paul D.
Kinahan, Paul E.
author_facet Lastwika, Kristin J.
Wu, Wei
Zhang, Yuzheng
Ma, Ningxin
Zečević, Mladen
Pipavath, Sudhakar N. J.
Randolph, Timothy W.
Houghton, A. McGarry
Nair, Viswam S.
Lampe, Paul D.
Kinahan, Paul E.
author_sort Lastwika, Kristin J.
collection PubMed
description SIMPLE SUMMARY: Indeterminate pulmonary nodules detected by computer tomography are a common clinical finding, but the path to determine malignancy can cause harm to patients. We aimed to comprehensively assess other types of noninvasive information that could help clinicians diagnose lung cancer, including semantic imaging features, quantitative radiomic imaging features and proteomic, glycomic, and autoantibody–antigen complex blood-based biomarkers. Utilizing these data, we generated a malignancy risk prediction model called PSR (plasma, semantic, radiomic) comprising nine imaging and molecular biomarkers. The PSR model performed well in two cohorts and against a clinical risk prediction model. Adding known clinical risk factors for lung cancer further improved the PSR model, indicating that our discovered markers held independent clinical utility. Our study revealed novel biomarkers and a risk prediction model to help assess cancer risk in patients with indeterminate pulmonary nodules. ABSTRACT: The clinical management of patients with indeterminate pulmonary nodules is associated with unintended harm to patients and better methods are required to more precisely quantify lung cancer risk in this group. Here, we combine multiple noninvasive approaches to more accurately identify lung cancer in indeterminate pulmonary nodules. We analyzed 94 quantitative radiomic imaging features and 41 qualitative semantic imaging variables with molecular biomarkers from blood derived from an antibody-based microarray platform that determines protein, cancer-specific glycan, and autoantibody–antigen complex content with high sensitivity. From these datasets, we created a PSR (plasma, semantic, radiomic) risk prediction model comprising nine blood-based and imaging biomarkers with an area under the receiver operating curve (AUROC) of 0.964 that when tested in a second, independent cohort yielded an AUROC of 0.846. Incorporating known clinical risk factors (age, gender, and smoking pack years) for lung cancer into the PSR model improved the AUROC to 0.897 in the second cohort and was more accurate than a well-characterized clinical risk prediction model (AUROC = 0.802). Our findings support the use of a multi-omics approach to guide the clinical management of indeterminate pulmonary nodules.
format Online
Article
Text
id pubmed-10341085
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103410852023-07-14 Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment Lastwika, Kristin J. Wu, Wei Zhang, Yuzheng Ma, Ningxin Zečević, Mladen Pipavath, Sudhakar N. J. Randolph, Timothy W. Houghton, A. McGarry Nair, Viswam S. Lampe, Paul D. Kinahan, Paul E. Cancers (Basel) Article SIMPLE SUMMARY: Indeterminate pulmonary nodules detected by computer tomography are a common clinical finding, but the path to determine malignancy can cause harm to patients. We aimed to comprehensively assess other types of noninvasive information that could help clinicians diagnose lung cancer, including semantic imaging features, quantitative radiomic imaging features and proteomic, glycomic, and autoantibody–antigen complex blood-based biomarkers. Utilizing these data, we generated a malignancy risk prediction model called PSR (plasma, semantic, radiomic) comprising nine imaging and molecular biomarkers. The PSR model performed well in two cohorts and against a clinical risk prediction model. Adding known clinical risk factors for lung cancer further improved the PSR model, indicating that our discovered markers held independent clinical utility. Our study revealed novel biomarkers and a risk prediction model to help assess cancer risk in patients with indeterminate pulmonary nodules. ABSTRACT: The clinical management of patients with indeterminate pulmonary nodules is associated with unintended harm to patients and better methods are required to more precisely quantify lung cancer risk in this group. Here, we combine multiple noninvasive approaches to more accurately identify lung cancer in indeterminate pulmonary nodules. We analyzed 94 quantitative radiomic imaging features and 41 qualitative semantic imaging variables with molecular biomarkers from blood derived from an antibody-based microarray platform that determines protein, cancer-specific glycan, and autoantibody–antigen complex content with high sensitivity. From these datasets, we created a PSR (plasma, semantic, radiomic) risk prediction model comprising nine blood-based and imaging biomarkers with an area under the receiver operating curve (AUROC) of 0.964 that when tested in a second, independent cohort yielded an AUROC of 0.846. Incorporating known clinical risk factors (age, gender, and smoking pack years) for lung cancer into the PSR model improved the AUROC to 0.897 in the second cohort and was more accurate than a well-characterized clinical risk prediction model (AUROC = 0.802). Our findings support the use of a multi-omics approach to guide the clinical management of indeterminate pulmonary nodules. MDPI 2023-06-29 /pmc/articles/PMC10341085/ /pubmed/37444527 http://dx.doi.org/10.3390/cancers15133418 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lastwika, Kristin J.
Wu, Wei
Zhang, Yuzheng
Ma, Ningxin
Zečević, Mladen
Pipavath, Sudhakar N. J.
Randolph, Timothy W.
Houghton, A. McGarry
Nair, Viswam S.
Lampe, Paul D.
Kinahan, Paul E.
Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment
title Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment
title_full Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment
title_fullStr Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment
title_full_unstemmed Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment
title_short Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment
title_sort multi-omic biomarkers improve indeterminate pulmonary nodule malignancy risk assessment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341085/
https://www.ncbi.nlm.nih.gov/pubmed/37444527
http://dx.doi.org/10.3390/cancers15133418
work_keys_str_mv AT lastwikakristinj multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT wuwei multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT zhangyuzheng multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT maningxin multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT zecevicmladen multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT pipavathsudhakarnj multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT randolphtimothyw multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT houghtonamcgarry multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT nairviswams multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT lampepauld multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment
AT kinahanpaule multiomicbiomarkersimproveindeterminatepulmonarynodulemalignancyriskassessment